Evidence map›Paper›PMID 35508525›Full record

ArticleScientific reports2022

AAV9-mediated functional screening for cardioprotective cytokines in Coxsackievirus-B3-induced myocarditis.

Paolo Carai, Giulia Ruozi, Alexandra Paye, Yannick Debing, Francesca Bortolotti, Julie Lecomte, Lorena Zentilin, Elizabeth A V Jones, Mauro Giacca, Stephane Heymans

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. LncGBP9 knockdown alleviates myocardial inflammation and apoptosis in mice with acute viral myocarditis via suppressing NF-κB signaling pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Paolo CaraiDepartment of Cardiovascular Sciences, Center for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium.
Giulia RuoziInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
Alexandra PayeCARIM, Maastricht University, Maastricht, The Netherlands.
Yannick DebingCARIM, Maastricht University, Maastricht, The Netherlands.
Francesca BortolottiInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
Julie LecomteCARIM, Maastricht University, Maastricht, The Netherlands.
Lorena ZentilinInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
Elizabeth A V JonesDepartment of Cardiovascular Sciences, Center for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium.
Mauro GiaccaInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
Stephane HeymansDepartment of Cardiovascular Sciences, Center for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium. s.heymans@maastrichtuniversity.nl.
Maastricht University · NLInternational Centre for Genetic Engineering and Biotechnology · ITKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral myocarditis (VM) is an important cause of heart failure (HF) in children and adults. However, the molecular determinants involved in cardiac inflammation and cardiomyocyte necrosis remain poorly characterized, and cardioprotective molecules are currently missing. Here, we applied an in vivo method based on the functional selection (FunSel) of cardioprotective factors using AAV vectors for the unbiased identification of novel immunomodulatory molecules in a Coxsackievirus B3 (CVB3)-induced myocarditis mouse model. Two consecutive rounds of in vivo FunSel using an expression library of 60 cytokines were sufficient to identify five cardioprotective factors (IL9, IL3, IL4, IL13, IL15). The screening also revealed three cytokines (IL18, IL17b, and CCL11) that were counter-selected and likely to exert a detrimental effect. The pooled overexpression of the five most enriched cytokines using AAV9 vectors decreased inflammation and reduced cardiac dilatation, persisting at 1 month after treatment. Individual overexpression of IL9, the top ranking in our functional selection, markedly reduced cardiac inflammation and injury, concomitant with an increase of anti-inflammatory Th2-cells and a reduction of pro-inflammatory Th17- and Th22-cells at 14 days post-infection. AAV9-mediated FunSel cardiac screening identified IL9 and other four cytokines (IL3, IL4, IL13, and IL15) as cardioprotective factors in CVB3-induced VM in mice.

Indexed as

Coxsackievirus InfectionsMyocarditisAnimalsCytokinesDisease Models, AnimalEnterovirus B, HumanInflammationInterleukin-13Interleukin-15Interleukin-4Interleukin-9MiceMice, Inbred BALB CCytokinesInterleukin-13Interleukin-15Interleukin-4Interleukin-9

Identifiers

PMID35508525
PMCPMC9067557
OpenAlexW4229005338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.